Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on ODM-203 PK in healthy males
NCT03240445Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aur109 in solid tumor (3 arms), sponsored by Orion Corporation. Primary endpoint: Area under the plasma concentration curve (AUC) of ODM-203. Started Aug 2017; status: completed.
02
Drugs
aur109
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03240445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240445.